Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | PRKX | P51817 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24049389 | 0.91 | NPBWR1 (0.45) | MAOBMAOAACHEMAPT | |
| SCHEMBL24049141 | 0.91 | NPBWR1 (0.45) | MAOBMAOAACHEMAPT | |
| SCHEMBL26065108 | 0.85 | HDAC1 (0.43) | MAPT | |
| SCHEMBL24049297 | 0.79 | LMNA (0.46) | MAPT | |
| SCHEMBL24049393 | 0.79 | ALDH1A1 (0.48) | MAPT | |
| SCHEMBL26065087 | 0.73 | GRIN2C (0.55) | POLB | |
| SCHEMBL24049388 | 0.73 | GRIN2C (0.55) | — | |
| SCHEMBL26065084 | 0.71 | MAPT (0.40) | S1PR1S1PR5PDGFRANR4A2MAOB | |
| SCHEMBL24049402 | 0.66 | GRIN2C (0.66) | — | |
| SCHEMBL24049401 | 0.66 | GRIN2C (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355593-A1 | N-methyl-D-aspartic Acid Receptor Modulators | UNIV EMORY (US) | 2023-11-09 | — | — | US | disclosed |
| US-11738008-B2 | N-methyl-D-aspartic acid receptor modulators | EMORY UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355593-A1 | N-methyl-D-aspartic Acid Receptor Modulators | GRIN1, GRIN2A, GRM1 | S1PR1 1635/4885S1PR5 1991/4885PDGFRA 884/4885 |
| US-11738008-B2 | N-methyl-D-aspartic acid receptor modulators | GRIN1, GRIN2A, GRM1 | S1PR1 1614/4885S1PR5 2024/4885PDGFRA 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.